Coya Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
COYA$3.16-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $32,626,768 | $5,933,702 |
| Collaboration receivable | 7,500,000 | - |
| Prepaids and other current assets | 1,069,557 | 1,251,264 |
| Total current assets | 41,196,325 | 7,184,966 |
| Fixed assets, net | 65,949 | 93,310 |
| Deferred financing costs | - | 1,117,290 |
| Total assets | $41,262,274 | $8,395,566 |
| Liabilities and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,155,656 | $1,815,270 |
| Accrued expenses | 2,973,215 | 2,008,361 |
| Deferred collaboration revenue | 923,109 | - |
| Total current liabilities | 5,051,980 | 3,823,631 |
| Deferred collaboration revenue | 574,685 | - |
| Convertible promissory notes | - | 12,965,480 |
| Total liabilities | 5,626,665 | 16,789,111 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity (deficit): | ||
| Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none and 7,500,713 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | - | 8,793,637 |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 14,405,325 and 2,590,197 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 1,441 | 259 |
| Additional paid-in capital | 61,501,801 | 681,106 |
| Subscription receivable | (11,250) | - |
| Accumulated deficit | (25,856,383) | (17,868,547) |
| Total stockholders' equity (deficit) | 35,635,609 | (8,393,545) |
| Total liabilities and stockholders' equity (deficit) | $41,262,274 | $8,395,566 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.